great notice on shawonline

NAL is focused on commercialising leading edge technology such as laser assisted drug delivery devices and immunology technology. The company has placed initial orders for the production of its device and expects to generate high margin revenue on the sale of disposable accessories. NAL's immunology technology will enter clinical trials in 2004 ahead of FDA approval expected afterwards. This will trigger milestone payments and subsequent royalty payments should trial results prove successful. We expect a strong market response to this technology and value NAL at $2.53 per share.

I especially love their timing!